BR112015015635A2 - inibidores de quinases de proteínas - Google Patents
inibidores de quinases de proteínasInfo
- Publication number
- BR112015015635A2 BR112015015635A2 BR112015015635A BR112015015635A BR112015015635A2 BR 112015015635 A2 BR112015015635 A2 BR 112015015635A2 BR 112015015635 A BR112015015635 A BR 112015015635A BR 112015015635 A BR112015015635 A BR 112015015635A BR 112015015635 A2 BR112015015635 A2 BR 112015015635A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- protein kinase
- compounds
- present
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Abstract
resumo “inibidores de quinases de proteínas” a presente invenção refere-se a compostos da fórmula (i) a seguir: (i) e/ou seus sais de adição, solvatos, enantiômeos e diaestereoisômeros farmaceuticamente aceitáveis, bem como suas misturas. o objeto da presente invenção também inclui, portanto, a preparação de compostos da fórmula (i), seus usos, particularmente na inibição de quinases de proteínas que são relacionadas, por exemplo, a diversas doenças, tais como cânceres ou distúrbios do sistema imunológico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261747031P | 2012-12-28 | 2012-12-28 | |
FR1262932A FR3000493A1 (fr) | 2012-12-28 | 2012-12-28 | Nouveaux inhibiteurs de proteines kinases |
PCT/EP2013/078138 WO2014102376A1 (en) | 2012-12-28 | 2013-12-30 | Protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015015635A2 true BR112015015635A2 (pt) | 2017-07-11 |
BR112015015635A8 BR112015015635A8 (pt) | 2018-01-23 |
Family
ID=47989196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015015635A BR112015015635A8 (pt) | 2012-12-28 | 2013-12-30 | composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão |
Country Status (12)
Country | Link |
---|---|
US (1) | US9403823B2 (pt) |
EP (1) | EP2938612A1 (pt) |
JP (1) | JP2016504345A (pt) |
KR (1) | KR20150108845A (pt) |
CN (1) | CN105008354A (pt) |
AU (1) | AU2013369241A1 (pt) |
BR (1) | BR112015015635A8 (pt) |
CA (1) | CA2896813A1 (pt) |
FR (1) | FR3000493A1 (pt) |
HK (1) | HK1215577A1 (pt) |
RU (1) | RU2015128605A (pt) |
WO (1) | WO2014102376A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
CN105636951B (zh) * | 2014-04-14 | 2018-05-15 | 上海恒瑞医药有限公司 | 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
SI3322706T1 (sl) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CA3143525A1 (en) * | 2019-06-28 | 2020-12-30 | Gb002, Inc. | Heterocyclic kinase inhibitors and products and uses thereof |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
IL293866A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of amorphous kinase inhibitors and methods of using them |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
MX2022014295A (es) * | 2020-05-25 | 2022-12-07 | Chiesi Farm Spa | Derivados de la bencilamina como inhibidores de los receptores del dominio de discoidina. |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0610828A2 (pt) * | 2005-05-16 | 2010-07-27 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
EP1919910B1 (en) * | 2005-07-29 | 2011-02-23 | F. Hoffmann-La Roche AG | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
MX2009002010A (es) * | 2006-09-06 | 2009-03-05 | Hoffmann La Roche | Derivados de heteroarilo como inhibidores de la proteina cinasa. |
JP5244118B2 (ja) * | 2006-11-10 | 2013-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | 新規キナーゼ阻害剤 |
WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
BRPI0814423B1 (pt) * | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
FR2928180B1 (fr) | 2008-02-28 | 2010-04-02 | Airbus France | Ensemble moteur pour aeronef comprenant une structure annulaire de transfert d'efforts entourant le carter central d'un turboreacteur. |
CA2716951A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2010017150A1 (en) * | 2008-08-05 | 2010-02-11 | Abbott Laboratories | Compounds useful as inhibitors of protein kinases |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
-
2012
- 2012-12-28 FR FR1262932A patent/FR3000493A1/fr not_active Withdrawn
-
2013
- 2013-12-30 JP JP2015550095A patent/JP2016504345A/ja active Pending
- 2013-12-30 CA CA2896813A patent/CA2896813A1/en not_active Abandoned
- 2013-12-30 WO PCT/EP2013/078138 patent/WO2014102376A1/en active Application Filing
- 2013-12-30 RU RU2015128605A patent/RU2015128605A/ru not_active Application Discontinuation
- 2013-12-30 BR BR112015015635A patent/BR112015015635A8/pt not_active IP Right Cessation
- 2013-12-30 CN CN201380071997.3A patent/CN105008354A/zh active Pending
- 2013-12-30 EP EP13814998.4A patent/EP2938612A1/en not_active Withdrawn
- 2013-12-30 AU AU2013369241A patent/AU2013369241A1/en not_active Abandoned
- 2013-12-30 US US14/655,605 patent/US9403823B2/en not_active Expired - Fee Related
- 2013-12-30 KR KR1020157020246A patent/KR20150108845A/ko not_active Application Discontinuation
-
2016
- 2016-03-25 HK HK16103533.0A patent/HK1215577A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013369241A1 (en) | 2015-07-16 |
US9403823B2 (en) | 2016-08-02 |
CN105008354A (zh) | 2015-10-28 |
JP2016504345A (ja) | 2016-02-12 |
FR3000493A1 (fr) | 2014-07-04 |
CA2896813A1 (en) | 2014-07-03 |
EP2938612A1 (en) | 2015-11-04 |
HK1215577A1 (zh) | 2016-09-02 |
KR20150108845A (ko) | 2015-09-30 |
RU2015128605A (ru) | 2017-02-02 |
BR112015015635A8 (pt) | 2018-01-23 |
US20160009709A1 (en) | 2016-01-14 |
WO2014102376A1 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015015635A2 (pt) | inibidores de quinases de proteínas | |
BR112015015653A2 (pt) | derivados de azaindol como inibidores de quinases de proteínas | |
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
BR112015003859A2 (pt) | compostos de pirazolopirimidina como inibidores de quinase | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
BR112012020693A2 (pt) | derivados de ciclobutano e metilciclobutano como inibidores de janus quinase | |
BR112015027951A8 (pt) | arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
BR112017024933A8 (pt) | Alvocidib produce com a bioavailabilidade aumentada | |
CU20150078A7 (es) | Derivados de cicloalquilo pirrolo [2, 3-d]pirimidina -4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos | |
BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
BR112015021701A2 (pt) | novos compostos inibidores da fosfoestearase tipo 10a | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
BR112015022861A8 (pt) | inibidores de bromodomínio | |
BR112015014701B8 (pt) | Derivados de benzimidazol e seus usos | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
BR112013019354A2 (pt) | derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inibidores de fosfodiesterases | |
BR112014029708A2 (pt) | composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |